Silicosis
Also known as: Silica-induced pneumoconiosis, Silicotic pneumoconiosis, Crystalline silica-associated lung disease
Silicosis is a fibrotic pneumoconiosis resulting from the inhalation of respirable crystalline silica. The pathology may progress following cessation of exposure, necessitating specialist respiratory and occupational medicine review, rigorous exposure mitigation, and longitudinal monitoring. Traditional Chinese Medicine (TCM) provides a symptomatic management framework but must not delay diagnostic investigation or supersede specialist intervention, immunisation, or pharmacotherapy. Cited evidence [1–3] examines cellular mechanisms in animal and in vitro models rather than establishing clinical efficacy for herbal medicine or acupuncture in human subjects with silicosis. Furthermore, the nicotine-withdrawal trial [4] involved a distinct cohort and failed to demonstrate improved smoking abstinence. Traditional patterns and formulas described herein are not evidence-based interventions for pulmonary fibrosis.
Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.
Lifestyle & Diet
- •Cease all further respirable silica exposure and consult occupational health services regarding workplace engineering controls and alternate duties, as personal protective equipment may be insufficient.
- •Utilise evidence-based smoking-cessation interventions and avoid environmental tobacco smoke; note that research into electroacupuncture has not demonstrated improved abstinence rates.
- •Adhere to a structured pulmonary rehabilitation programme and pace activities of daily living to avoid exertion beyond established physiological limits.
- •Maintain optimal nutritional status, attend scheduled respiratory monitoring, and discuss indicated vaccinations with the primary treating clinician.
Cautions & Contraindications
- •Do not substitute experimental targets, herbal extracts or traditional formulas for respiratory care. Sources [1–3] are animal or cell studies and establish neither patient benefit nor clinical dosing or safety.[,,]
- •Do not extrapolate the purified plant-polysaccharide findings to whole-herb safety, commercial products or self-treatment; the supplied study does not establish those conclusions.[]
- •Avoid deep thoracic or upper-back needling because pneumothorax could be particularly hazardous in someone with impaired respiratory reserve. This is a general procedural precaution; source [1] describes the fibrotic disease context, not needling safety.[]
- •Electroacupuncture requires device-specific assessment in people with implanted electronic devices; defer treatment during unstable respiratory illness. These are general precautions, not safety findings established by the supplied nicotine-withdrawal trial.[]
When to reassess or seek care again
Record baseline breathlessness score, cough severity on a 0–10 scale, sleep disruption, sputum changes and a patient-selected daily activity. Review after 2–4 weeks of any adjunctive trial and stop if there is no meaningful symptom or functional improvement. Follow lung-function and oxygenation monitoring on the respiratory team's schedule; symptom relief must not be interpreted as reversal of fibrosis. Refer promptly for declining activity tolerance, weight loss, new haemoptysis or worsening breathlessness; escalate emergency findings immediately.
Explore more diseases
Sources & Further Reading
Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.
- Cellular signalling · 2026
- Pharmaceuticals (Basel, Switzerland) · 2026
- Phytomedicine : international journal of phytotherapy and phytopharmacology · 2026
- Therapeutics and clinical risk management · 2026
Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.
